Jinxin Fertility Secures Strategic Investment Led by Warburg Pincus and CSCI to Accelerate Global Expansion

Jinxin Fertility Completes New Round of Financing

VCBeat (WeChat ID: vcbeat) has learned that Jinxin Fertility recently completed a major transaction, led by its existing strategic shareholder Warburg Pincus and CITIC Bank International Limited (“CITIC Bank International”), a subsidiary of China CITIC Bank Corporation Limited (“China CITIC Bank”) newly introduced into the deal. Follow-on investors included Sequoia China, WuXi AppTec, and others, fully reflecting investors’ confidence in the industry as well as in Jinxin Fertility’s investment value and prospects.

In recent years, assisted reproductive technology (ART) has become one of the fastest-growing potential markets in the healthcare services industry, with its broad development prospects attracting significant attention from investors.

According to available information, all investors participating in this equity investment in Jinxin Fertility are well-known investment institutions with extensive experience and strong reputations, reflecting the market’s confidence in the industry and the company’s corporate value, competitive advantages, and significant growth potential.

Among them, Warburg Pincus is a globally leading private equity investment firm, currently managing over $45 billion in private equity assets, and possesses extensive experience and a strong track record in China’s healthcare services sector. Warburg Pincus made its initial investment in Jinxin Fertility in the second half of 2017.

As CITIC Bank’s overseas boutique investment bank, CIB International Capital is actively advancing various investment banking license-based businesses and proprietary fund investment and financing activities in Hong Kong, while vigorously expanding its private equity fund management operations both domestically and internationally. Following the completion of this round of financing, Warburg Pincus and CIB International Capital have become the second and third largest shareholders of Jinxin Fertility respectively, bringing synergistic benefits to Jinxin Fertility’s business, helping accelerate its expansion into overseas markets, and deepening its global strategic layout.

As demand for assisted reproductive services continues to rise, China’s assisted reproduction market is poised to maintain robust growth. Leveraging its market-leading position and competitive advantages, Jinxin Fertility is well-positioned to capitalize on these growth opportunities and achieve sustainable expansion.

Regarding this financing round, Jinxin Fertility stated, “We are honored to partner with leading investment institutions. This not only signifies the market’s trust in the Company but also underscores our determination to enhance core competitiveness, further expand our business, adhere to an internationalization strategy, and increase our market share. We firmly believe that introducing strong shareholders will help the Group achieve further growth and development, solidify its foundation, and become stronger and larger.”

Fang Min, Partner at Warburg Pincus, stated, “We are pleased to increase our stake in Jinxin Fertility by leading this round of financing. Population growth and the transformation of socioeconomic development in the Chinese market will continue to drive consumption growth in the healthcare sector. Warburg Pincus is highly optimistic about the future of the assisted reproductive technology (ART) industry and Jinxin Fertility. We will leverage Warburg Pincus’s resources and experience in the healthcare sector both domestically and internationally to assist Jinxin Fertility in further strengthening its leading position in the domestic market while actively expanding into overseas markets.”

The head of CITIC Capital Investments also stated, “As a leader in the field of assisted reproductive technology (ART), Jinxin Fertility has consistently remained at the international forefront of clinical reproductive medicine, continuously achieving new breakthroughs in its specialized domain. The Group’s business performance and investment value have also been steadily enhancing. CITIC Capital Investments is pleased to have this opportunity to become a shareholder of Jinxin Fertility. We will work closely with other shareholders to integrate various high-quality resources and support the Group’s further development.”

Jinxin Fertility’s institutions have developed into an international professional service provider in the field of assisted reproductive technology, committed to building a multidisciplinary, cross-regional reproductive health service system with advanced medical technologies. Its portfolio includesThree Major Assisted Reproductive Technology Centers: Chengdu Xinan, Shenzhen Zhongshan, and HRC Fertility (USA)。

Jinxin Fertility Group Affiliates

Chengdu Xinan has 20 years of experience in IVF in China and is the first medical institution in Sichuan Province approved by the National Ministry of Health to provide human assisted reproductive technology services. Shenzhen Zhongshan is also the first reproductive assistance center established in Shenzhen, with its number of oocyte retrieval cycles and clinical pregnancy rates ranking among the top in China.

HRC Fertility, a US-based entity under its umbrella, boasts a 30-year history as the largest assisted reproductive technology (ART) center on the US West Coast in terms of treatment cycles. HRC has consistently remained at the forefront of ART application, being the first center on the US West Coast to achieve a pregnancy via intracytoplasmic sperm injection (ICSI) and the first nationwide to perform preimplantation genetic diagnosis (PGD). According to the latest data released by the US Centers for Disease Control and Prevention (CDC), HRC’s success rates for both fresh and frozen embryo transfers significantly lead the nation.

Jinxin Fertility boasts an authoritative team of experts in reproductive endocrinology and infertility, as well as a top-tier team of scientists specializing in in vitro embryo manipulation and genetic testing. With world-class professional medical expertise, extensive clinical experience, and internationally leading theoretical knowledge and practical techniques, the company has consistently remained at the forefront of international reproductive clinical practice. It has received numerous domestic and international awards in the field and continues to achieve new technological breakthroughs in both professional care and laboratory operations.

Leveraging its competitive advantages, Jinxin Fertility has become one of the few assisted reproductive technology (ART) institutions in China capable of competing on par with the leading local public hospitals.

Furthermore, since 2016, Jinxin Fertility has attracted numerous renowned domestic and international investors, including Warburg Pincus from the United States, through multiple rounds of financing. Leveraging its existing top-tier specialist team, the company is committed to creating internationally premier hospital environments and state-of-the-art facilities, thereby providing patients with professional medical services that meet global standards.

Looking ahead, Jinxin Fertility will continue to enrich and diversify its shareholder base through close collaboration with international investment institutions. Meanwhile, by leveraging the experience and resources of all parties involved as well as the Group’s expertise, it will expand synergies in the medical and capital sectors, laying a solid foundation for sustained and healthy development in the future.